# Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

> **NCT06204809** · PHASE1 · COMPLETED · sponsor: **PepGen Inc** · enrollment: 24 (actual)

## Conditions studied

- Myotonic Dystrophy 1

## Interventions

- **DRUG:** PGN-EDODM1 for infusion
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06204809
- **Lead sponsor:** PepGen Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-12
- **Primary completion:** 2025-10-28
- **Final completion:** 2025-10-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06204809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06204809, "Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06204809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*